Optic nerve hypoplasia is a very appalling eye disease that kids are born with the optic nerve unfledged. With this congenital eye ailment, kids’ both eyes cannot see. Before, optic nerve hypoplasia means that individuals were inept to see in their entire life. But now, with the development of stem cell therapy, the condition can be rehabilitated and these poor kids still have the likelihood to see this beautiful world. Essentially, there is a lengthy list of patients who have been treated with optic nerve hypoplasia stem cell therapy and lived a new life. Cheers to the stem cell therapy. Honestly we hope that there will be more kids with optic nerve hypoplasia can be treated with this effective treatment and lead a cheerier life.
Optic nerve hypoplasia (ONH) befalls from the underdevelopment of the optic nerve, which carries neuronal transmission from the retina in the eye to the brain. Septo-optic dysplasia (SOD) — also acknowledged as de Morsier syndrome — is a subtype of ONH and stems from underdevelopment of the optic nerve, pituitary gland dysfunction and lack of the septum pellucidum, which is a midline zone of the brain. SOD ascends from shortcomings during the embryological development of babies and studies show that ONH might be connected to gene shortcomings as well as embryo exposure to infections. In addition to the absence of vision which is a characteristic symptom of ONH, SOD also triggers other symptoms such as pituitary deficiency, autistic conducts, epileptic seizures, etc.
Few conventional treatment choices are available for patients spotted with ONH-SOD, which typically concentrate on helping the patients to deal with their infirmity. However, none of them are really treating the loss of optic nerve function. Stem cells have the aptitude to regenerate nerve cells in the optic nerve, permitting ONH-SOD patients to attain some vision. In the past some years, the medical community has seen a burst of knowledge and has felt watchful confidence regarding the future usage of cell-based therapies for several diseases including blinding illnesses of kids. In general, these prospective therapies are concentrated on stem cells. Lately, newfangled treatments using cell-based methods have been encouraged for patients with otherwise fatal inherited ocular malformations such as optic nerve hypoplasia. Optic Nerve Hypoplasia (ONH) and Septo-optic Dysplasia (de Morsier Syndrome) are two of the congenital disorders for which hospitals can offer access to pioneering stem cell treatment. This offers new healing potentials beyond old-style treatment choices